Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465467 | 0.98 | ALDH1A1 (0.65) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL465533 | 0.98 | ALDH1A1 (0.65) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL465539 | 0.94 | HPGD (0.69) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL7630422 | 0.92 | ALDH1A1 (0.58) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL23627223 | 0.92 | HPGD (0.58) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL3083583 | 0.91 | FFAR1 (0.60) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL3843475 | 0.90 | FFAR1 (0.59) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL9098252 | 0.90 | FFAR1 (0.59) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL8551794 | 0.88 | ALDH1A1 (0.69) | HPGDALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL4052838 | 0.88 | HPGD (0.57) | HPGDALDH1A1SMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194981-B1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | UNIV MONS HAINAUT (BE) | 2011-11-23 | — | — | EP | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| EP-2194981-A1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | Université de Mons-Hainaut (BE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009043902-A1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | UNIVERSITE DE MONS HAINAUT (BE) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | NQO2, SQOR, CPS1 | HPGD 2305/4885ALDH1A1 2545/4885SMN1; SMN2 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.